SPDL1 and cancer: Furthermore, these dataprovide evidence that SNAs and gene knockdown pathways can be usedas an alternative to traditional checkpoint inhibitors in cancer immunotherapy.This is an attractive approach to immunotherapy since sPD-L1 is notalways a viable target because of the dynamic nature of protein expressionand the ever-changing TME.